Skip to main content Skip to main menu
UF Health University of Florida
Division of Hematology & Oncology Department of Medicine in the College of Medicine
Aline Fares

Aline Fares, MD

CLIN ASO PROF

Department: MD-HEMATOLOGY-ONCOLOGY-OTHER
Business Phone: (352) 273-8010
Business Email: aline.fares@ufl.edu

On This Page

About Aline Fares

My name is Aline Fares and I’m a medical oncologist at UF Health, specializing in thoracic oncology with a focus on lung cancer. I completed my medical training at the Faculty of Medicine of Catanduva and pursued a residency in internal medicine at the Faculty of Medicine of São José do Rio Preto. I then specialized in medical oncology at AC Camargo Cancer Center and completed a fellowship in thoracic oncology at the University of Toronto’s Princess Margaret Cancer Centre.

Both of my parents are physicians, and growing up, I was inspired by their deep compassion and dedication to patient care. Their example guided me toward a career in medicine, and over time, my own love for forming meaningful connections with people naturally drew me to oncology. Building strong, lasting relationships with my patients is the most fulfilling part of my work.

In my role, I’m committed to advancing patient care through clinical research and mentorship. I’m especially interested in exploring how physical exercise, nutrition, and lifestyle factors can impact lung cancer outcomes. Outside of work, I enjoy spending time with my husband, our daughters, our dogs and my parents. I love cooking Mediterranean-style meals, making sure my family eats well, and staying active, especially with weightlifting, my favorite sport!

Teaching Profile

Courses Taught

  1. MDC7203 – Senior Medicine Clerk

    College of Medicine

Clinical Profile

Specialties

  • Medical Oncology

Areas of Interest

  • Cancer
  • Lung Cancer
  • Metastatic Brain Tumor

Publications

Academic Articles

Grants

  1. A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

    Active

    Role:
    Principal Investigator
    Funding:
    MERCK SHARP & DOHME

  2. A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV 706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    Active

    Role:
    Principal Investigator
    Funding:
    ABBVIE

  3. A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2)

    Active

    Role:
    Principal Investigator
    Funding:
    SYNEOS HEALTH via GENENTECH INC

  4. A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE- Lung04)

    Active

    Role:
    Principal Investigator
    Funding:
    ASTRAZENECA PHARM

  5. A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)

    Active

    Role:
    Principal Investigator
    Funding:
    ASTRAZENECA PHARM

  6. A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

    Active

    Role:
    Principal Investigator
    Funding:
    NRG ONCOLOGY FOU via NATL INST OF HLTH NCI

  7. A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFRMutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Active

    Role:
    Principal Investigator
    Funding:
    JANSSEN RESEARCH AND DEVELOPMENT

  8. UF HEALTH CANCER CENTER PILOT PROJECTS GRANTS FUNDED THROUGHTHE FLORIDA CONSORTIUM OF NATIONAL CANCER INSTITUTE CENTER

    Active

    Role:
    Project Manager
    Funding:
    UF HEALTH SHANDS HOSPITAL

Contact Details

Phones:
Business:
(352) 273-8010
Emails:
Business:
aline.fares@ufl.edu
Addresses:
Business Street:
2033 MOWRY RD STE 145
 GAINESVILLE FL 32610